Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2017

09.06.2017

Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination

verfasst von: R. Pannell, S. Li, V. Gurewich

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Thrombolysis with tissue plasminogen activator (tPA) has been a disappointment and has now been replaced by an endovascular procedure whenever possible. Nevertheless, thrombolysis remains the only means by which circulation in a thrombosed artery can be restored rapidly. In contrast to tPA monotherapy, endogenous fibrinolysis uses both tPA and urokinase plasminogen activator (uPA), whose native form is a proenzyme, prouPA. This combination is remarkably effective as evidenced by the fibrin degradation product, d-dimer, which is invariably present in plasma. The two activators have complementary mechanisms of plasminogen activation and are synergistic in combination. Since tPA initiates fibrinolysis when released from the vessel wall and prouPA is in the blood, they induce fibrinolysis sequentially. It was postulated that this may be more effective and fibrin-specific. The hypothesis was tested in a model of clot lysis in plasma in which a clot was first exposed to tPA for 5 min, washed and incubated with prouPA. Lysis was compared with that of clots incubated with both activators simultaneously. The sequential combination was almost twice as effective and caused less fibrinogenolysis than the simultaneous combination (p < 0.0001) despite having significantly less tPA, as a result of the wash. A mechanism is described by which this phenomenon can be explained. The findings are believed to have significant therapeutic implications.
Literatur
1.
Zurück zum Zitat Voskuilen M, Vermond A, Veeneman GH, van Boom JH, Klasen EA, Zegers ND, Nieuwenhuizen W (1987) Fibrinogen lysine residue Aα157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem 262(13):5944–5946PubMed Voskuilen M, Vermond A, Veeneman GH, van Boom JH, Klasen EA, Zegers ND, Nieuwenhuizen W (1987) Fibrinogen lysine residue Aα157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem 262(13):5944–5946PubMed
2.
Zurück zum Zitat Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912–2919PubMed Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912–2919PubMed
3.
Zurück zum Zitat Liu J, Gurewich V (1992) Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (Ala-158-rpro-UK). BioChemistry 31:6311–6317CrossRefPubMed Liu J, Gurewich V (1992) Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (Ala-158-rpro-UK). BioChemistry 31:6311–6317CrossRefPubMed
4.
Zurück zum Zitat Liu J, Gurewich V (1991) A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 88:2012–2017CrossRefPubMedPubMedCentral Liu J, Gurewich V (1991) A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 88:2012–2017CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Petersen LC (1997) Kinetics of reciprocal pro-urokinase/plasminogen activation. Stimulation by a template formed by the urokinase receptor bound to poly (d-lysine). Eur J Biochem 245:316–323CrossRefPubMed Petersen LC (1997) Kinetics of reciprocal pro-urokinase/plasminogen activation. Stimulation by a template formed by the urokinase receptor bound to poly (d-lysine). Eur J Biochem 245:316–323CrossRefPubMed
6.
Zurück zum Zitat Pannell R, Black J, Gurewich V (1988) The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 81:853–859CrossRefPubMedPubMedCentral Pannell R, Black J, Gurewich V (1988) The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 81:853–859CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Gurewich V, Pannell R (1987) Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost 57:372–378PubMed Gurewich V, Pannell R (1987) Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost 57:372–378PubMed
8.
Zurück zum Zitat Liu JN, Tang W, Sun ZY, Kung W, Pannell R, Sarmientos P, Gurewich V (1996) A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. BioChemistry 35:14070–14076CrossRefPubMed Liu JN, Tang W, Sun ZY, Kung W, Pannell R, Sarmientos P, Gurewich V (1996) A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. BioChemistry 35:14070–14076CrossRefPubMed
9.
Zurück zum Zitat Liu JN, Liu JX, Liu B, Sun Z, Zuo JL, Zhang P, Zhang J, Chen Y, Gurewich V (2002) A prourokinase mutant which induces highly effective clot lysis without interfering with hemostasis. Circu Res 90:757–763CrossRef Liu JN, Liu JX, Liu B, Sun Z, Zuo JL, Zhang P, Zhang J, Chen Y, Gurewich V (2002) A prourokinase mutant which induces highly effective clot lysis without interfering with hemostasis. Circu Res 90:757–763CrossRef
10.
Zurück zum Zitat Pannell R, Li S, Gurewich V (2015) Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. PLoS ONE 10:1–15CrossRef Pannell R, Li S, Gurewich V (2015) Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK. PLoS ONE 10:1–15CrossRef
11.
Zurück zum Zitat Dmitry V, Sakharov J, Nagelkerke F, Dingeman C, Rijken DC (1996) Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 271:2133–2138CrossRef Dmitry V, Sakharov J, Nagelkerke F, Dingeman C, Rijken DC (1996) Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 271:2133–2138CrossRef
12.
Zurück zum Zitat Suenson E, Lützen O, Thorsen S (1984) Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 140:513–522CrossRefPubMed Suenson E, Lützen O, Thorsen S (1984) Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 140:513–522CrossRefPubMed
13.
Zurück zum Zitat Harpel PC, Chang TS, Verderber E (1985) Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem 260(7):4432 (abstr)PubMed Harpel PC, Chang TS, Verderber E (1985) Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem 260(7):4432 (abstr)PubMed
14.
Zurück zum Zitat Gurewich V (2016) Therapeutic fibrinolysis. How efficacy and safety can be improved. J Am Coll Cardiol 68:2099–2106CrossRefPubMed Gurewich V (2016) Therapeutic fibrinolysis. How efficacy and safety can be improved. J Am Coll Cardiol 68:2099–2106CrossRefPubMed
15.
Zurück zum Zitat Liu J, Pannell R, Gurewich V (1992) A transitional state of pro-urokinase which has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 267:15289–15292PubMed Liu J, Pannell R, Gurewich V (1992) A transitional state of pro-urokinase which has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 267:15289–15292PubMed
16.
Zurück zum Zitat Baglin TP, Landown R, Frasson R, Huntington JA (2016) Discovery and characterization of an antibody directed against exosite 1 of thrombin. J Thrommb Haemos 14:137–142CrossRef Baglin TP, Landown R, Frasson R, Huntington JA (2016) Discovery and characterization of an antibody directed against exosite 1 of thrombin. J Thrommb Haemos 14:137–142CrossRef
17.
Zurück zum Zitat Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Rømer J, Danø K, Carmeliet P, Collen D, Degen JL (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93:5899–5904CrossRefPubMedPubMedCentral Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Rømer J, Danø K, Carmeliet P, Collen D, Degen JL (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93:5899–5904CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B, Smith A (2003) Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 107:869–875CrossRefPubMed Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B, Smith A (2003) Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 107:869–875CrossRefPubMed
19.
Zurück zum Zitat Pannell R, Gurewich V (1992) A comparison of the rates of clot lysis in a plasma milieu induced by tissue plasminogen activator (t-PA) and rec-prourokinase: evidence that t-PA has a more restricted mode of action. Fibrinolysis 6:1–5CrossRef Pannell R, Gurewich V (1992) A comparison of the rates of clot lysis in a plasma milieu induced by tissue plasminogen activator (t-PA) and rec-prourokinase: evidence that t-PA has a more restricted mode of action. Fibrinolysis 6:1–5CrossRef
20.
Zurück zum Zitat Vaughan DE, Vautloutle E, Collen D (1990) Urokinase binds to platelets through a specific saturable, low affinity mechanism. Fibrinolysis 4:141CrossRef Vaughan DE, Vautloutle E, Collen D (1990) Urokinase binds to platelets through a specific saturable, low affinity mechanism. Fibrinolysis 4:141CrossRef
21.
Zurück zum Zitat Gurewich V, Johnstone MT, Pannell R (1995) The selective uptake of high molecular weight urokinase-type plasminogen activator by human platelets. Fibrinolysis 9:188–195CrossRef Gurewich V, Johnstone MT, Pannell R (1995) The selective uptake of high molecular weight urokinase-type plasminogen activator by human platelets. Fibrinolysis 9:188–195CrossRef
22.
Zurück zum Zitat Grau E, Moroz LA (1989) Fibrinolytic activity of normal human blood monocytes. Thromb Res 53:145–162CrossRefPubMed Grau E, Moroz LA (1989) Fibrinolytic activity of normal human blood monocytes. Thromb Res 53:145–162CrossRefPubMed
23.
Zurück zum Zitat Gurewich V, Emmons F, Pannell R (1988) Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: demonstration of a promoting effect by tPA and by platelets on urokinase. Fibrinolysis 2:143–149CrossRef Gurewich V, Emmons F, Pannell R (1988) Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: demonstration of a promoting effect by tPA and by platelets on urokinase. Fibrinolysis 2:143–149CrossRef
24.
Zurück zum Zitat Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V for the PATENT Study Group (1995) Sequential combination thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial. J Am Coll Cardio 26:374–379CrossRef Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V for the PATENT Study Group (1995) Sequential combination thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial. J Am Coll Cardio 26:374–379CrossRef
25.
Zurück zum Zitat Ross AM for the GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622CrossRef Ross AM for the GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622CrossRef
Metadaten
Titel
Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination
verfasst von
R. Pannell
S. Li
V. Gurewich
Publikationsdatum
09.06.2017
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2017
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1514-0

Weitere Artikel der Ausgabe 2/2017

Journal of Thrombosis and Thrombolysis 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.